Lilly Novo Nordisk Battle Intensifies as Obesity Drugs Surge
Eli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
When To Switch From Target Date Fund To Age Based Approach: Go. This intro covers when a switch makes sense and what signals to watch for in your plan.
25,368 articlesEli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
A revealing look at how the crypto world got swept up in an illusion of money and momentum. Learn what happened, why ...
OpenAI has begun allowing users to link bank accounts to ChatGPT, turning the chatbot into a real-time financial assi...
Two AI stock contenders show different paths for growth and profits. This guide explains how to read quarterly revenu...
Amazon is quietly expanding its in-house silicon beyond data center basics, pushing Graviton and Trainium into broade...
In 2025, Sophia Genetics is at a crossroads between expanding its software platform and tightening its financial disc...
Can Apple land another market-moving hit? This analysis weighs the signals, metrics, and scenarios investors should w...
Zscaler executives argue that AI cannot substitute for 100% reliable inline traffic inspection, even as AI workloads ...
What could happen to NuScale Power stock over the next five years? This article breaks down the catalysts, scenarios,...
Syndicate Labs, a16z-backed, is closing its development arm after five years of building on-chain tooling, blaming a ...
Nick Saban urged lawmakers to curb explosive growth in college athletics as Congress weighs a sweeping reform bill. T...
Ad fraud powered by generative AI is pressuring the digital ad market. A growing number of firms turning blockchain f...